The syndrome of apparent mineralocorticoid excess arises from nonfunctional mutations in 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2), an enzyme that inactivates cortisol and confers aldosterone specificity on the mineralocorticoid receptor. Loss of 11␤HSD2 permits glucocorticoids to activate the mineralocorticoid receptor, and the hypertension in the syndrome is presumed to arise from volume expansion secondary to renal sodium retention. An 11␤HSD2 null mouse was generated on an inbred C57BL/6J genetic background, allowing survival to adulthood. 11␤HSD2 Ϫ/Ϫ mice had BP approximately 20 mmHg higher on average compared with wild-type mice but were volume contracted, not volume expanded as expected. Initially, impaired sodium excretion associated with increased activity of the epithelial sodium channel was observed. By 80 days of age, however, channel activity was abolished and 11␤HSD2 Ϫ/Ϫ mice lost salt. Despite the natriuresis, hypertension remained but was not attributable to intrinsic vascular dysfunction. Instead, urinary catecholamine levels in 11␤HSD2 Ϫ/Ϫ mice were double those in wild-type mice, and ␣1-adrenergic receptor blockade rescued the hypertensive phenotype, suggesting that vasoconstriction contributes to the sustained hypertension in this model. In summary, it is proposed that renal sodium retention remains a key event in apparent mineralocorticoid excess but that the accompanying hypertension changes from a renal to a vascular etiology over time. In 90% of hypertensive patients, the causal pathophysiology cannot be defined and, in 25%, BP fails to fall to target values with existing therapies. Improved understanding of pathogenesis is key to addressing this problem. Fundamental principles of BP homeostasis have been established through investigation of the rare Mendelian hypertensive disorders. These disorders result almost exclusively from mutations in genes encoding proteins influencing directly or indirectly sodium balance, 1 suggesting that altered renal salt homeostasis is a key factor in the misregulation of BP 2 The fine-tuning of sodium balance is achieved in the distal nephron, determined principally by the actions of aldosterone at the mineralocorticoid receptor (MR). In vitro, MR can be activated with equal potency by both mineralocorticoids and glucocorticoids. 3 In vivo, ligand access is determined by the enzyme 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2), which catalyzes the rapid conversion of the active glucocorticoid cortisol (corticosterone in mice) to inert cortisone (11-dehydrocorticosterone), thereby 
In 90% of hypertensive patients, the causal pathophysiology cannot be defined and, in 25%, BP fails to fall to target values with existing therapies. Improved understanding of pathogenesis is key to addressing this problem. Fundamental principles of BP homeostasis have been established through investigation of the rare Mendelian hypertensive disorders. These disorders result almost exclusively from mutations in genes encoding proteins influencing directly or indirectly sodium balance, 1 suggesting that altered renal salt homeostasis is a key factor in the misregulation of BP 2 The fine-tuning of sodium balance is achieved in the distal nephron, determined principally by the actions of aldosterone at the mineralocorticoid receptor (MR). In vitro, MR can be activated with equal potency by both mineralocorticoids and glucocorticoids. 3 In vivo, ligand access is determined by the enzyme 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2), which catalyzes the rapid conversion of the active glucocorticoid cortisol (corticosterone in mice) to inert cortisone (11-dehydrocorticosterone), thereby conferring on MR the specificity to aldosterone that it inherently lacks. 4, 5 In the kidney, 11␤HSD2 is expressed in the connecting tubule and in the principal cells of the cortical (CCD) and outer medullary collecting duct. 6 Acute pharmacologic inhibition of the enzyme promotes collecting duct sodium reabsorption 7 via increased activity of the epithelial sodium channel (ENaC). 8 Inactivating mutations in the gene HSD11B2, which encodes 11␤HSD2, cause the syndrome of apparent mineralocorticoid excess (SAME; OMIM #218030). In this setting, cortisol activates MR, 9 -12 resulting in severe hypertension thought to arise from volume expansion secondary to renal sodium retention. 9, 11, 13, 14 Suppression of cortisol by administration of synthetic glucocorticoids that do not activate MR is therapeutically effective, 12 and in one case, full correction of the disorder was achieved by renal transplantation, 15 highlighting the central role of the kidney in SAME.
These human genetic studies suggest that 11␤HSD2 is a physiologic regulator of BP, but investigation of key mechanisms is not possible in patients because the disease is rare and most patients are children. We originally modeled SAME by targeted disruption of the 11␤HSD2 locus in an outbred (MF1) mouse strain, 16 but the high neonatal mortality permitted only limited physiologic examination. We have now transferred the targeted mutation onto the C57BL/6J genetic background, which attenuates the neonatal mortality while retaining the cardinal features of the disease. Using a time course stretching from weaning to early adulthood, we have identified key mechanistic events in the development and maintenance of hypertension in SAME. Ϫ/Ϫ mice and aged-matched C57BL/6J mice. Data are means Ϯ SEM. Comparisons were made using ANOVA with Bonferroni post hoc test. *P Ͻ 0.05; **P Ͻ 0.01. The expression of ENaC-␣ protein was below the detection threshold in kidneys from C57BL/6 mice (E), consistent with a previous report, but was localized to the apical membrane in the CCD of 60-d-old 11␤HSD2 Ϫ/Ϫ mice (F).
RESULTS

Sustained Hypertension but Transient Sodium Retention in 11␤HSD2
؊/؊ Mice 11␤HSD2 Ϫ/Ϫ mice had elevated mean arterial BP (MABP) at each of the four time points studied ( Figure 1A ). Fractional sodium excretion was reduced by Ͼ50% in 11␤HSD2 Ϫ/Ϫ mice at 35 and 60 d of age ( Figure 1B) , during which time amiloridesensitive sodium reabsorption was doubled ( Figure 1C ). Quantitative PCR showed increased renal expression of ENaC-␣ mRNA in 35-and 60-d-old 11␤HSD2 Ϫ/Ϫ mice (Figure 1D) . Expression of ENaC-␤ and ENaC-␥ were higher in 11␤HSD2 Ϫ/Ϫ mice than in controls, although this reached statistical significance only for ENaC-␥ (P Ͻ 0.01; data not shown). The expression of MR was similar in both groups. ENaC-␣ immunoreactivity in the CCD and outer medullary collecting duct, not detectable in the C57BL/6J mice at any age ( Figure 1E ), 17 was evident in 60-d-old 11␤HSD2 Ϫ/Ϫ mice, demonstrating increased protein abundance. Strong apical membrane localization was observed ( Figure 1F ). At 80 d of age, 11␤HSD2
Ϫ/Ϫ mice exhibited natriuresis, with fractional sodium excretion being normalized by 120 d (Figure 2A ). The mechanism of escape was identified: the natriuretic impact of amiloride was lost in 80-and 120-d-old 11␤HSD2 Ϫ/Ϫ mice ( Figure 2B ). The downregulation of functional channel activity does not rely principally on attenuation of transcriptional or translational processes because both ENaC-␣ mRNA levels ( Figure 2C ) and renal immunoreactivity remained higher in 11␤HSD2 Ϫ/Ϫ mice than in controls ( Figure 2D ). Ϫ/Ϫ mice, showing that immunoreactivity is predominately cytoplasmic. Western analysis shows the relative expression of SGK1 (E) and Nedd4 (F) in the kidney (n ϭ 6 for each group) of 11␤HSD2 Ϫ/Ϫ mice, as a ratio of that in kidneys of age-matched C57BL/6J mice. The dotted line shows the level of equal expression. Protein quantification was by densitometry. All data are means Ϯ SEM. Comparisons were made using ANOVA with Bonferroni post hoc test or, for E and F, a one-sample t test assuming a sample mean of 1.0. *P Ͻ 0.05; **P Ͻ 0.01. BASIC RESEARCH www.jasn.org was displaced from the apical membrane of the collecting duct principal cells ( Figure 2D ), suggesting that altered channel trafficking underpins the transition from a sodium-retaining to sodium-shedding state. Western blotting analysis was therefore used to measure the renal abundance of two key ENaC trafficking proteins 18 : Serum glucocorticoid regulated kinase 1 (SGK1), which promotes insertion of the ENaC into the apical membrane of the principal cell; and neural precursor cell-expressed, developmentally downregulated protein type 4 (Nedd4), which causes channel removal by ubiquitination. 18 SGK1 expression was approximately seven-fold higher in 11␤HSD2 Ϫ/Ϫ mouse kidney (P Ͻ 0.01) at 35 d of age ( Figure  2E ). Levels of Nedd4 were significantly reduced in 11␤HSD2 Ϫ/Ϫ mice at both 35 and 60 d of age (P Ͻ 0.01; Figure  2F ). At 80 d, expression of both proteins was comparable between groups; however, by 120 d of age, renal expression of SGK1 was reduced whereas that of Nedd4 was enhanced in 11␤HSD2 Ϫ/Ϫ mice. Figure 3E ). Many severely hypertrophied cells had loss of basal striations and had extensive accumulations of basophilic granules throughout the cytoplasm, changes suggestive of subcellular disorganization ( Figure  3F ). These marked changes of the renal epithelium were limited to the distal convoluted tubule: The segments of the collecting duct appeared anatomically normal during the course of study.
Altered ENaC Trafficking in 11␤HSD2
؊/؊ Mice In 120-d-old 11␤HSD2 Ϫ/Ϫ mice, ENaC-␣ immunoreactivity
Volume-Contracted Hypertension in 11␤HSD2
؊/؊ Mice Renal sodium retention was not associated with volume expansion. Indeed, hematocrit was significantly increased in all cohorts of 11␤HSD2 Ϫ/Ϫ mice, indicating plasma volume contraction ( Figure 4A ). Blood volume was measured directly in a separate group of mice, and the approximately 30% reduction in 11␤HSD2 Ϫ/Ϫ mice confirmed ( Figure 4B ). The renin-angiotensin-aldosterone system, normally activated with plasma volume contraction, was suppressed: Plasma aldosterone was significantly lower in 11␤HSD2 Ϫ/Ϫ mice (Table 1) as was kidney renin mRNA, levels being Ͻ30% of controls in all age groups (P Ͻ 0.05). Plasma corticosterone concentrations were comparable between genotypes at all time points (Table 1 ). There was a significant hypernatremia ( Figure 4C ) and elevated plasma osmolality (Table 1) at all time points studied. Despite this, urine flow rate was approximately doubled and urine osmolality markedly reduced in 11␤HSD2 Ϫ/Ϫ mice ( Table 1 ). The increase in free water clearance in 11␤HSD2 Ϫ/Ϫ mice (Table 1) , inappropriate given the hypertonicity, is suggestive of a urine-concentrating defect. This may result from the progressive hypokalemia observed in We assessed endothelium-dependent vasodilation and sensitivity to catecholamines of sections of thoracic aorta from 11␤HSD2 Ϫ/Ϫ mice or age-matched controls. The effects of acetylcholine and noradrenaline in each of the four age groups are shown if Figure 5 . The maximum response to acetylcholine was reduced in 11␤HSD2 Ϫ/Ϫ mice only in the 60-d-old group ( Figure 5B , Table 2 ). Because vasodilator responses to sodium nitroprusside in 11␤HSD2 Ϫ/Ϫ mice were comparable to those in controls during this study (Table 2) , the reduced response to acetylcholine at 60 d of age relates to endothelial cell dysfunction, rather than altered sensitivity to nitric oxide. The maximum response and sensitivity to noradrenaline was not increased in 11␤HSD2 Ϫ/Ϫ null mice at any age ( Figure 5 , Table  2 ). Indeed, there is trend toward a reduction in noradrenalinemediated contraction in the 35-and 60-d-old groups ( Figure 5 , A and B).
11␤HSD2
؊/؊ Mice Have Increased Catecholamine Levels
In the absence of increased sensitivity to catecholamines of the vasculature ex vivo, urinary excretion of adrenaline and noradrenaline was measured and found to be substantially elevated in 11␤HSD2 Ϫ/Ϫ mice ( Figure 6A ). To assess directly the contribution of catecholamines to the maintenance of hypertension, we measured the impact on MABP of acute ␣1-adrenoreceptor blockade in vivo. A bolus of prazosin significantly reduced MABP in both groups of mice (Ͼ120 d of age; Figure  6 , B and C, for sample traces), but the effect of the drug was substantially greater in the 11␤HSD2 Ϫ/Ϫ mice (Ϫ22.3 Ϯ 1.4 versus Ϫ8.7 Ϯ 1.1 mmHg; n ϭ 5/6; P Ͻ 0.001). Importantly, ␣1-adrenoreceptor blockade rescued the hypertensive phenotype in 11␤HSD2 Ϫ/Ϫ mice ( Figure 6D ). DISCUSSION SAME is characterized by unregulated glucocorticoid activation of MR after ablation of 11␤HSD2. 9 -12 Hypertension in this disorder is thought to be renal in origin, relating to enhanced ENaC-mediated sodium reabsorption and volume expansion. 7, 8, 14 In this study, we used 11␤HSD2 Ϫ/Ϫ mice to model SAME and demonstrated that transient abnormal renal function can promote a chronic hypertensive cascade that is not sustained through volume expansion.
Initially, 11␤HSD2 Ϫ/Ϫ mice had an impaired ability to excrete sodium, relating to increased expression of ENaC subunits and enhanced activity of the functional channel shown by the increased natriuretic potency of amiloride. We also found increased expression of SGK1 and reduced expression of Nedd4 during this period, which combined would increase the membrane retention time of ENaC. 18 SGK1 is established as an early aldosterone response gene in the kidney. 19 In contrast, Nedd4 protein levels are not effected by acute administration of aldosterone 20, 21 ; however, our findings and those in a recent a Data are means Ϯ SE. Statistical comparisons were made using ANOVA with least significant difference post hoc test. ANOVA indicated significant effect of genotype in all four variables. There was no effect of age per se for any variable, but there was a significant interaction between age and genotype for U Osm (P Ͻ 0.01), FWC (P Ͻ 0.01), and P K (P Ͻ 0.01). FWC, free water clearance; P Aldo , plasma concentration of aldosterone; P Cort , plasma concentration of corticosterone; P K , plasma concentration of potassium; P Osm , plasma osmolality; U Osm , urine osmolality b P Ͻ 0.05. c P Ͻ 0.01.
study 22 indicate that chronic activation of MR leads to decreased collecting duct expression of Nedd4-2. A key finding of our study is that the kidney is able to circumvent a genetic obligation for avid sodium reabsorption. By the 80-d time point, 11␤HSD2
Ϫ/Ϫ mice displayed enhanced sodium excretion. The escape from perceived mineralocorticoid excess does not rely on attenuation of transcriptional or translational processes because ENaC-␣ mRNA and CCD protein levels remained higher in 11␤HSD2 Ϫ/Ϫ mice than in controls during this period. Our data suggest that ENaC is rendered physiologically inactive because, in the CCD at least, it is not trafficked to the apical membrane. We have not confirmed Ϫ/Ϫ mice (f) and age-matched C57BL/6J mice (E). Mice were studied at 35 (A), 60 (B), 80 (C), and 120 d of age (D) with six mice per genotype used at each time point. Concentration-response curves to acetylcholine are shown on the left and to noradrenalin on the right. Data are means Ϯ SEM of the percentage relaxation/contraction to the response induced by 5-hydroxytryptamine/potassium chloride, respectively. Comparisons were made using either t test or ANOVA with a Bonferroni post hoc test. **P Ͻ 0.01.
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altered ENaC trafficking in either the late distal convoluted tubule or the connecting tubule. That the natriuretic impact of amiloride was lost, however, indicates that functional channel activity is abolished throughout the distal nephron. The mechanisms underpinning trapping in the cytosol may, in the longer term, involve an alteration in the balance between insertion and retrieval, but ENaC is functionally inactivated before any changes in expression of SGK1 or Nedd4 are apparent. The loss of functional ENaC explains why amiloride is only an effective means of long-term BP control 12, 23 in SAME when used at the high dosages 24 required to inhibit proximal tubule sodium transport. 25 A generalized transport defect could be indicated, so extensive histopathologic examination of 11␤HSD2 Ϫ/Ϫ mouse kidneys was performed.
In some patients with SAME, the kidney is grossly normal, 10 but cysts, nephrocalcinosis, and hypertensive end-organ damage are seen in others, particularly as the disease progresses. 26 We showed progressive changes of the renal epithelium in 11␤HSD2 Ϫ/Ϫ mice, but, surprisingly, these were limited to the distal convoluted tubule: the segments of the collecting duct appeared anatomically normal. Because the mouse distal convoluted tubule does not express 11␤HSD2, 6 these changes must be secondary to the deletion of the gene in other nephron segments. The structural changes are strongly reminiscent of those occurring in the rat after long-term exposure to loop diuretics such as furosemide. 27 We propose that impaired sodium reabsorption in the loop of Henle, secondary to potassium depletion, promotes a compensatory hypertrophy of the distal convoluted tubule. The use of thiazide diuretics to inhibit sodium chloride co-transport in this segment would therefore be specifically indicated for long-term BP regulation in SAME. 10, 24 Our analysis suggests that downregulation of ENaC is not caused by gross changes in collecting duct structure.
A striking outcome of this study is the marked volume contraction observed in 11␤HSD2 Ϫ/Ϫ mice, even during the period of enhanced sodium reabsorption. Human 28 and animal studies 29 have consistently shown volume expansion in the early, prehypertensive stage of experimental mineralocorticoidism. In this situation, volume expansion increases cardiac output, initiating hypertension, which is then maintained in the adaptive phase by peripheral vasoconstriction. 30 In most forms of hypertension, peripheral resistance is high and blood volume is either normal or slightly low (reviewed by Hamlyn and Blaustein 29 and Cowley 31 ) during the chronic phase. The volume contraction observed in 11␤HSD2 Ϫ/Ϫ mice may therefore represent the postadaptive period of hypertension, and we cannot exclude a period of volume expansion before 35 d of age.
To explain volume contraction in the face of sodium reten- tion, we have two connected hypotheses. The first is that sodium retention is "water-free," being held in osmotically inactive stores. This occurs in the DOCA-salt model of mineralocorticoid hypertension and minimizes the impact on extracellular fluid volume to buffer BP. 32 The second hypothesis is that water homeostasis is disturbed in 11␤HSD2 Ϫ/Ϫ mice, hydration being insufficient to expand or even maintain blood volume. The hypernatremia observed in 11␤HSD2
Ϫ/Ϫ mice throughout the experimental period supports the hypothesis but does not explain the phenomenon. Although 11␤HSD2 Ϫ/Ϫ mice are polyuric, most probably as a result of nephrogenic diabetes insipidus secondary to potassium depletion, 33 they are also polydipsic. It is unclear why a volume balance is not achieved: 11␤HSD2-containing neurons in the nucleus of the solitary tract are stimulated by chronic hypovolemia, 34 and pharmacologic inhibition of the enzyme promotes thirst. 35 It may be that a fully operational renin-angiotensin system, suppressed in this model, is required to match precisely intake to output.
Although progressive potassium depletion models accurately the untreated human syndrome, it confounds elucidation of the hypertensive mechanism in 11␤HSD2 Ϫ/Ϫ mice. Potassium depletion can influence BP through various mechanisms 36, 37 : Membrane depolarization promotes contraction of vascular smooth muscle, and vascular tone can be influenced indirectly by impaired endothelium-dependent vasodilation, increased sympathetic outflow, and depression of baroreceptor sensitivity. Similar effects are also found with hypernatremia, 38 a consistent feature in 11␤HSD2 Ϫ/Ϫ mice and one sustained beyond the downregulation of ENaC activity. Traditionally, sodium is considered the chief culprit in hypertension, with potassium being assigned a minor role; however, evidence from both human population studies, such as the DASH (Dietary Approaches to Stop Hypertension) or Intersalt trials, combined with experiments in animals models, suggest that an isolated derangement in one or the other is of lesser importance than their interaction. 36 In this study, the electrolyte disturbances seem inextricably linked: Enhanced sodium reabsorption in the distal nephron would stimulate potassium secretion, and the resulting potassium depletion would cause volume contraction and hypernatremia.
Because volume expansion does not seem to underpin hypertension in 11␤HSD2
Ϫ/Ϫ mice, we measured the intrinsic contractile properties of the conduit vasculature. Vascular tissue contains both glucocorticoid receptors and MR, activation of which can sensitize vascular smooth muscle to the effects of Ϫ/Ϫ mice (f; n ϭ 5) and agematched C57BL/6J mice (Ⅺ; n ϭ 6). Data are means Ϯ SEM, and comparisons were made using either t test or ANOVA with a Bonferroni post hoc test. **P Ͻ 0.01. Sample BP recordings are shown for C57BL/6J mice (C) and 11␤HSD2 Ϫ/Ϫ mice (D).
BASIC RESEARCH www.jasn.org vasopressors. 39 11␤HSD2 is localized to the vascular endothelium, 40 and inhibition of the enzyme increases vascular sensitivity to angiotensin II 41 and catecholamines. 42 Vascular reactivity to noradrenaline is enhanced in a patient with SAME, 43 and we have found significant endothelial dysfunction in the outbred MF1 mouse model of SAME at 120 d of age, 44 although not increased sensitivity to noradrenaline. In this study, however, we found only limited evidence for enhanced vascular contractility in 11␤HSD2 Ϫ/Ϫ mice, and this was transient. We conclude that changes in the intrinsic properties of the conduit vasculature do not make a major contribution to the development or maintenance of hypertension in this model of SAME. That the vascular phenotype is not observed on the C57BL/6J background implicates protective modifier loci that influence the physiologic function of the MR pathway.
Increased urinary excretion of catecholamines was observed in 11␤HSD2 Ϫ/Ϫ mice, which plausibly reflects increased sympathetic nerve activity. 45 Adrenoreceptor blockade was shown, at least acutely, to rescue the hypertensive phenotype. Extending this observation to the clinical situation, antiadrenergics, including the vasodilator dihydralazine, have been used to treat SAME in patients who do not respond to either MR blockade or cortisol suppression. 10 The mechanism underlying increased sympathetic activity is unknown but could result from either potassium depletion 36 or sodium retention. 38 Our findings demonstrate that renal sodium retention is transient and amiloride-sensitive sodium reabsorption is downregulated in 11␤HSD2 Ϫ/Ϫ mice. In the chronic phase, hypertension is not sustained through either volume expansion or direct vascular dysfunction. We propose that the key hypertensive event is an electrolyte disturbance that activates the sympathetic nervous system, consistent with marked volume depletion. 29 
CONCISE METHODS
A congenic mouse strain was generated by backcross of the MF1 11␤HSD2 Ϫ/Ϫ mouse with C57BL/6J. All mice used in this study were obtained from homozygous null breeding after 12 generations of backcross onto C57BL/6J (Harlan, Bicester, UK). Age-matched C57BL/6J were used as controls. Following this extensive backcross, the congenic strain will be genetically Ͼ99.9% identical to the parent inbred strain. 46 Although we did not use littermate wild types as controls, it is highly likely that the phenotypes reported reflect the targeted disruption of hsd11b2 contained in the non-C57BL/6J chromosomal fragment.
In a separate group of 12th-generation congenics, heterozygote intercrosses were used to demonstrate that the three genotypes (identified as described previously 16 ) were present at birth in the normal Mendelian ratio. In contrast to the original outbred strain, the congenic 11␤HSD2 Ϫ/Ϫ mice exhibited no abnormal occurrence of neonatal death. Four age groups of mice were used in this study: 35, 60, 80, and 120 (Ϯ3) d of age. The time points were selected to cover the maturation of renal function from weaning to adulthood, with the final time point being in the stable period of adult kidney function in the C57BL/6J mouse. 47 All experiments were performed in accordance with the UK Home Office (Scientific Procedures) Act 1986.
In Vivo Studies
Renal function experiments were performed as described previously. 48 Mice were infused intravenously with a saline solution containing 1% FITC-inulin at a rate of 0.2 ml/h per 10 g body wt. A 60-min equilibration period was followed by two consecutive periods (45 min each) of renal function measurements, sandwiched by collection of a 20-l blood sample. After the first (control) collection, amiloride (2 mg/kg intravenously; Sigma, Poole, UK) was administered, and, after a 10-min equilibration period, a second urine collection was made. MABP was measured throughout (PowerLab; ADInstruments, Oxford, UK). At the end of the experiment, a 500-l blood sample was taken for measurements of aldosterone and corticosterone, and the kidneys were removed.
In separate groups of mice, (1) plasma volume was determined by injection of Evans Blue (1 l/g of a 0.5% wt/vol solution intravenously) and blood volume was calculated from plasma volume and hematocrit, (2) the effect of acute ␣1 adrenoreceptor blockade was measured by monitoring of the effect of a bolus of prazosin (0.1 mg/ kg; Sigma) on MABP, and (3) 24-h urinary excretion of adrenalin and noradrenalin was measured by ELISA (CatCombi; IBL, Hamburg, Germany).
Histopathologic Analyses
Kidneys were immersion-fixed in 10% neutral buffered formalin for 48 h followed by paraffin embedding. Four-micron sections were stained with hematoxylin and eosin and examined by a specialist in rodent pathology (D.G.B.).
Protein Studies
Total protein was extracted from one half kidney by homogenization, separated by SDS-PAGE (10 g of total protein per lane), and blotted to polyvinylidene difluoride membrane. Immunoblotting using rabbit polyclonal antibodies (Upstate, Lake Placid, NY) against either Nedd4 or SGK1 was performed according to the manufacturer's protocols, detecting a protein of 115 and 50 kD, respectively. Coomassie Blue staining of parallel samples was performed to determine equal protein loading. The localization of ENaC-␣ was determined by immunohistochemical staining on 5-m sections of perfusion-fixed kidney from a separate group of age-matched mice, as described previously 17 using a polyclonal antibody provided by Dr. J. Loffing (University of Fribourg, Fribourg, Switzerland).
Quantitative PCR
Total RNA was prepared from whole kidneys, and mRNA of interest were quantified by commercial assays according to the manufacturer's instructions using an ABI 7700 (Applied Biosystems, Warrington, UK). Data were normalized to 18S rRNA on a sample-to-sample basis.
